Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Depreciation and Depletion (2021 - 2025)

Aligos Therapeutics' Depreciation and Depletion history spans 5 years, with the latest figure at $257000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 13.22% year-over-year to $257000.0; the TTM value through Dec 2025 reached $951000.0, down 15.62%, while the annual FY2025 figure was $930000.0, 9.44% down from the prior year.
  • Depreciation and Depletion reached $257000.0 in Q4 2025 per ALGS's latest filing, up from $200000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $800000.0 in Q2 2021 to a low of $194000.0 in Q1 2025.
  • Average Depreciation and Depletion over 5 years is $453950.0, with a median of $417500.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: crashed 47.82% in 2024, then grew 13.22% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $709000.0 in 2021, then fell by 27.22% to $516000.0 in 2022, then dropped by 15.7% to $435000.0 in 2023, then plummeted by 47.82% to $227000.0 in 2024, then grew by 13.22% to $257000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Depreciation and Depletion are $257000.0 (Q4 2025), $200000.0 (Q3 2025), and $300000.0 (Q2 2025).